...
机译:FDA批准摘要:Dabrafenib和Trametinib用于治疗转移性非小细胞肺癌,含BRAF V600E BRAF V600E突变
Center for Drug Evaluation and Research U.S. Food and Drug AdministrationSilver Spring Maryland USA;
Center for Drug Evaluation and Research U.S. Food and Drug AdministrationSilver Spring Maryland USA;
Center for Drug Evaluation and Research U.S. Food and Drug AdministrationSilver Spring Maryland USA;
Center for Drug Evaluation and Research U.S. Food and Drug AdministrationSilver Spring Maryland USA;
Center for Drug Evaluation and Research U.S. Food and Drug AdministrationSilver Spring Maryland USA;
Center for Drug Evaluation and Research U.S. Food and Drug AdministrationSilver Spring Maryland USA;
Center for Drug Evaluation and Research U.S. Food and Drug AdministrationSilver Spring Maryland USA;
Center for Drug Evaluation and Research U.S. Food and Drug AdministrationSilver Spring Maryland USA;
Center for Drug Evaluation and Research U.S. Food and Drug AdministrationSilver Spring Maryland USA;
Center for Drug Evaluation and Research U.S. Food and Drug AdministrationSilver Spring Maryland USA;
Center for Drug Evaluation and Research U.S. Food and Drug AdministrationSilver Spring Maryland USA;
Center for Drug Evaluation and Research U.S. Food and Drug AdministrationSilver Spring Maryland USA;
Center for Drug Evaluation and Research U.S. Food and Drug AdministrationSilver Spring Maryland USA;
Center for Drug Evaluation and Research U.S. Food and Drug AdministrationSilver Spring Maryland USA;
Dabrafenib; Trametinib; Non‐small cell lung adenocarcinoma; BRAF V600E; BRAF mutation; Next‐generation sequencing; Companion diagnostic;
机译:FDA批准摘要:Dabrafenib和Trametinib用于治疗转移性非小细胞肺癌,含BRAF V600E BRAF V600E突变
机译:Dabrafenib和Trametinib疗法在一名老年患者中,患有BRAF v600E突变的非小细胞肺癌
机译:用OSIMERTINIB和DABRAFENIB PLUS TRAMETINIB治疗EGFR-19DEL / T790M / BRAF V600E突变的晚期肺腺癌的耐用临床响应:案例报告
机译:从概念到诊所的机器学习:使用高尺寸RNA表达数据可靠地检测甲状腺结节中的BRAF V600E DNA突变
机译:使用癌症的基因工程小鼠模型进行BRAF(V600E)诱导的非小细胞肺癌的遗传合作。
机译:FDA批准摘要:Dabrafenib和Trametinib用于治疗带有BRAF V600E突变的转移性非小细胞肺癌
机译:达布拉非尼联合曲美替尼在先前治疗过BRAF(V600E)突变型转移性非小细胞肺癌的患者中:一项开放性,多中心,2期试验